NYSE · Medical - Healthcare Information Services
CTEV (CTEV) Stock
$39.35
-1.21%
NYSE: CTEV
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
UnitedHealth Group (UNH) Faces Wider DOJ Antitrust Probe As Claritev Review Expands
Simply Wall St. · Jul 14, 2026
Sector Update: Healthcare Stocks Fall Late Afternoon
MT Newswires · Jul 14, 2026
Update: Market Chatter: DOJ Expands Antitrust Probe Into Claritev
MT Newswires · Jul 14, 2026
Sector Update: Healthcare Stocks Fall Tuesday Afternoon
MT Newswires · Jul 14, 2026
Market Chatter: DOJ Expands Antitrust Probe Into Claritev
MT Newswires · Jul 14, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held7.45%
Institutions Held91.02%
Institutions Float Held98.34%
Peer Comparison
About CTEV
CTEV is led by CEO Travis S. Dalton, publicly traded since 2020.
CTEV stock trades at $39.35 with a market capitalization of $670.83M. The stock is valued at a price-to-earnings (P/E) ratio of -2.21, price-to-book of -2.16, price-to-sales of 0.64. Over the past 52 weeks the stock has ranged between $11.50 and $74.07, and currently trades 46.9% below its 52-week high.
On profitability, CTEV generates a return on equity (ROE) of 139.56% — well above the market average, a sign of a high-quality business, return on capital employed of 1.08%, an operating margin of 4.66%, a net profit margin of -28.46%.